哮喘联盟

   摘要
   哮喘是一种伴有不同表型的慢性异质性炎性疾病。然而哮喘的临床特点是非特异性的且肺功能试验通常不敏感，因此有必要对哮喘的有效治疗乃至早期诊断作进一步研究。最近，已经出现一些具有哮喘诊断和管理价值的气道炎症生物标志物工具。气道炎症分子标志物检测是一项极具前景和非侵袭性的技术，可用于发现疾病的表型以及监测治疗效果。虽然常规治疗仍然是首选治疗方法，但却不能充分控制一些哮喘重症患者。新的治疗药物以参与炎症反应的各种生物标志物作为靶点，并已经在哮喘患者中进行了研究。
   本文对被研究得最多的哮喘生物标志物进行了概述，这些标志物来自于多种生物源，包括呼出气体、诱导痰、血清和尿液。同样，也讨论了目前哮喘抗炎治疗对于炎性生物标志物的影响，以及一些在新靶点治疗研发中具有前景的生物标志物。
 

（苏楠 审校）
Respirology. 2014 Apr 3.doi: 10.1111/resp.12284. [Epub ahead of print]

 

Biomolecular markers in assessment and treatment of asthma.
 

Fatemi F1, Sadroddiny E, Gheibi A, MohammadiFarsani T, Kardar GA.
 

ABSTRACT
Asthma is a chronic and heterogeneous inflammatory disorder with several different phenotypes. Whereas clinical features of asthma are non-specific and pulmonary function tests are often insensitive, further development is needed for efficient treatment or even early diagnosis. Recently, several airway inflammatory biomarkers have emerged as valuable tools in diagnosis and management of asthma. The analysis of molecular markers of airways inflammation has provided promising and non-invasive techniques that facilitate the detection of disease phenotypes as well as measurement of therapeutic efficacy. Although conventional treatments remain the preferred therapy, they do not adequately control some severe cases of asthma. Novel therapeutic agents have been developed to target various biomarkers involved in the inflammatory responses and have been investigated in patients with asthma. In this article, we summarized the most studied asthma biomarkers, derived from a variety of biological sources including exhaled gases, induced sputum, serum and urine. Likewise, the effects of current anti-inflammatory asthma treatments on inflammatory biomarkers and some promising biomarkers for developing new targeted therapies are also discussed.
 

Respirology. 2014 Apr 3.doi: 10.1111/resp.12284. [Epub ahead of print]